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Abstract
BACKGROUND—Neurofibromatosis type 1 (NF1) is a common genetic disorder characterized 
by plexiform neurofibromas (pNF), which are thought to be congenital tumors that arise in utero 
and enlarge throughout life. Genetic studies in murine models delineated an indispensable role for 
the stem cell factor (SCF)/c-kit pathway in pNF initiation and progression. A subsequent phase 2 
clinical trial using imatinib mesylate to inhibit SCF/c-kit demonstrated tumor shrinkage in a subset 
of pre-existing pNF, however imatinib’s role on preventing pNF development has yet to be 
explored.
PROCEDURE—We evaluated the effect of imatinib dosed at 10–100 mg/kg/day for 12 weeks to 
1-month old Nf1flox/flox;PostnCre(+) mice, prior to onset of pNF formation. To determine 
durability of response, we then monitored for pNF growth at later time points, comparing imatinib 
to vehicle treated mice. We assessed gross and histopathological analysis of tumor burden.
RESULTS—Imatinib administered preventatively led to a significant decrease in pNF number, 
even at doses as low as 10 mg/kg/day. Tumor development continued to be significantly inhibited 
after cessation of imatinib dosed at 50 and 100 mg/kg/day. In the cohort of treated mice that 
underwent prolonged follow-up, the size of residual tumors was significantly reduced as compared 
to age-matched littermates that received vehicle control.
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CONCLUSIONS—Early administration of imatinib inhibits pNF genesis in vivo and effects are 
sustained after discontinuation of therapy. These findings may guide clinical use of imatinib in 
young NF1 patients prior to substantial development of pNF.
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INTRODUCTION
Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder affecting 
about 1 in 3000 individuals worldwide [1]. Caused by heterozygous inactivating mutations 
in the NF1 tumor suppressor gene that encodes for neurofibromin, NF1 is characterized by a 
variety of clinical presentations including peripheral nervous system tumors. Plexiform 
neurofibromas (pNF) develop in 30–50% of patients with NF1 [2, 3] and are composed of 
proliferating neoplastic Schwann cells within a heterogeneous microenvironment of 
fibroblasts, macrophages, mast cells, perineurial cells, and secreted collagen [4–6]. The 
majority of pNF are detected in early childhood and progressively enlarge throughout life, 
with the highest growth rate in younger children [7–9]. These tumors are highly morbid via 
pain, motor, and sensory dysfunction related to involvement of nerve fascicles, can compress 
vital structures, and can lead to substantial visible disfigurement. Finally, the major cause of 
mortality in people with NF1 is malignant peripheral nerve sheath tumors (MPNSTs), which 
occur in approximately 10% of people with NF1 and arise from pNF burden [10].
Plexiform neurofibromas are thought to originate from Schwann cells or their early 
precursors [4, 6, 11–14], where aberrant stem cell factor (SCF)/c-kit signaling emanating 
from the tumor microenvironment promotes the initiation and growth of pNF lesions in 
genetically engineered mouse models (GEMM) [5]. Accordingly, imatinib mesylate, a 
potent inhibitor of c-kit, along with PDGFR and c-abl tyrosine kinases, induced the first 
objective clinical response seen in a therapeutic phase 2 trial in NF1 patients with pNF [15]. 
Over the past decade, further knowledge that neurofibromin loss results in hyperactivation of 
the Ras signaling cascade and other signal transduction networks has led to a variety of 
molecular targeted approaches and clinical trials for NF1-associated pNF [16–18], including 
inhibition of MEK [19], VEGF [20], and mTOR [21]. More recently, the role of nerve injury 
and subsequent inflammation in neurofibromagenesis has been evaluated, with the 
suggestion dual inhibition of both mast cells and macrophages may be effective [22]. 
Preclinical studies have also assessed the preventative role of MEK inhibition, which did not 
inhibit pNF development but did alter tumor size [23]. Despite these therapeutic advances, 
we are still faced with the challenge that not all existing pNF respond to targeted therapy and 
tumors often regrow when therapy is discontinued.
Capitalizing on previous observations that younger people with pNF that were smaller in 
total volume and located in the head, neck, and airway region had excellent tumor responses 
with imatinib [5,15], which is FDA approved for use in infants with leukemia, we evaluated 
the potential of imatinib for preventing the formation of pNF by blocking mast-cell 
recruitment to the microenvironment during the nascent stages of tumor development in 
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genetically engineered Nf1flox/flox; PostnCre(+) mice. Beginning at 1 month of life, 
preceding the earliest histological evidence of tumor formation, we determined that 
administering imatinib was sufficient to prevent pNF initiation. Further, when followed for 
20 weeks after cessation of imatinib, the number and size of residual tumors were 
significantly reduced as compared to littermates that received vehicle control. Collectively, 
these data demonstrate a proof of concept that imatinib may be effective as a preventative 
therapy for pNF with durable outcomes.
MATERIAL AND METHODS
Experimental Animals
The genetically engineered Nf1flox/flox;PostnCre(+) mice have been previously described 
[24, 25]. Animal care and experiments were conducted according to the guidelines 
established by the Indiana University Animal Care and Use Committee. Progeny from these 
crosses were genotyped by polymerase chain reaction as described previously [24].
In vivo Experimental Design and Drug Treatment Protocols
Weight-based doses of either imatinib or the vehicle control, phosphate buffered saline, were 
administered by daily oral gavage to cohorts of Nf1flox/flox;PostnCre(+) mice that were age 
and sex-matched as best as possible (details of sex in Supplemental Table 1). To determine 
the biological effect of varying doses of imatinib on preventing the development of pNFs, 
doses of 10, 25, 50, and 100 mg/kg of imatinib or vehicle control were administered daily 
for 12 weeks to cohorts of Nf1flox/flox;PostnCre(+) mice beginning at approximately 1 
month of life, prior to the onset of tumors (Supplemental Fig. 1). At the end of 12 weeks of 
therapy, the animals were euthanized for gross and histopathological analysis of tumor 
burden. Of note, by four months of life, Nf1flox/flox;PostnCre(+) mice develop plexiform 
neuorfibromas in multiple peripheral nerves with 100% penetrance [24, 25]. To determine 
whether early administration of imatinib results in stable tumor inhibition, 1 month old 
Nf1flox/flox;PostnCre(+) mice were treated with 50 and 100 mg/kg/day of imatinib or vehicle 
control for 12 weeks. Treatment was discontinued, and the mice were then euthanized at 20 
weeks following the end of drug therapy to evaluate for gross and histopathological evidence 
of tumor reemergence or progression.
Nerve Tree Microdissection and Measurement of Tumor Volume
Immediately postmortem, fresh tissues were harvested and mice were fixed in 10% neutral 
buffered formalin. The bodies were decalcified in 5% formic acid in 10% neutral buffered 
formalin solution. The proximal spinal nerve roots from the lumbosacral spine were 
dissected microscopically. The volume of proximal peripheral nerves was determined using 
calipers to measure the length and width of dissected tumors (or equivalent region in 
absence of tumor) in maximal dimension. Volume was approximated using the formula for 
the volume of a spheroid (0.52 × (width)2 × length) according to our previously established 
methodology [5].
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Microdissected nerve trees were embedded in 2% agar, processed through graded alcohols 
and xylenes, embedded in paraffin blocks, sectioned, and stained with hematoxylin and 
eosin and Masson’s trichrome to examine the tumor histomorphology and collagen 
deposition as described previously [4]. Infiltrating mast cells were identified on toluidine 
blue stained sections as previously reported [4]. Whole slide images were captured with an 
Aperio CS2 (Leica Biosystems, Buffalo Grove, IL).
Statistical Analysis
Statistical analyses were performed with GraphPad Prism 8.0 software (GraphPad, La Jolla, 
CA). Analysis of variance or Student’s T-tests was used to evaluate for differences between 
samples. P values less than 0.05 were considered significant with additional levels of 
significance as indicated.
RESULTS
Early Imatinib Mesylate Therapy Prevents Plexiform Neurofibroma Initiation
Nf1flox/flox;PostnCre(+) mice develop pNFs at 2–3 months of age and consistently have 
multiple pNFs by 4 months of age [24, 25]. Hence, we administered 10–100 mg/kg/day of 
imatinib or vehicle control to 1 month old Nf1flox/flox;PostnCre(+) mice, pre-pNF 
appearance (Fig. 1A). Proximal spinal nerve roots were microscopically dissected to 
enumerate resulting tumors after 12 weeks of treatment. At 100 mg/kg/day (the established 
MTD), we observed a 70% reduction in the mean number of pNF per animal. Most 
interestingly, this significant reduction in number of mean pNF per animal was maintained at 
all lower doses, including 10 mg/kg/day (10% of the MTD) (p<0.001) (Fig. 1B).
Sustained Plexiform Neurofibroma Growth Inhibition with Early Imatinib Mesylate Followed 
by Prolonged Treatment Cessation
The decrease in number of pNF following early imatinib treatment, especially at low doses, 
was encouraging. However, it remains unclear whether the tumor cells were eliminated or 
retain their proliferative potential. To address this question, cohorts of 
Nf1flox/flox;PostnCre(+) mice preventatively treated with 50 and 100 mg/kg/day of imatinib 
or vehicle control were monitored in prolonged follow-up after cessation of treatment for 20 
weeks before euthanasia (Fig. 2A). The mean number of pNF in mice previously treated 
with imatinib was 3.5 (at 50 mg/kg/day dosing) and 3.4 (at 100 mg/kg/day dosing) versus 
9.2 tumors per mouse in age matched vehicle controls (p<0.001) (Fig. 2B).
Alterations in the Plexiform Neurofibroma Microenvironment Persist Following 
Discontinuation of Imatinib Mesylate Treatment
Correlating with gross reduction of tumor number, histologic evaluation of dorsal root 
ganglia and proximal nerve roots in Nf1flox/flox;PostnCre(+) mice treated preventatively with 
imatinib versus vehicle treated controls showed inhibition of pNF genesis. Nerves harvested 
from vehicle treated mice demonstrated histological features characteristic of pNF including 
disrupted nerve architecture and increased cellularity, as compared to mice treated with 
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imatinib 50 or 100 mg/kg/day and immediately euthanized or followed for 20 weeks after 
therapy (Fig. 1C, Panels 1–3; Fig. 2C, Panels 1–3). Further, there was marked reduction in 
fibroblast collagen deposition (Fig. 1C, Panels 4–6; Fig. 2C, Panels 4–6; Supplemental Fig. 
2) and reduction in infiltrating mast cells (Fig. 1C, Panels 7–9; Fig. 2C, Panels 7–9) in 
nerves dissected from imatinib treated mice versus those from vehicle treated cohorts.
Sustained Attenuation of Plexiform Neurofibroma Growth Velocity with Early Imatinib 
Mesylate Therapy
In addition to evaluating the potential of preventing tumor initiation in young mice, we also 
sought to delineate the impact of early imatinib treatment on residual pNF that do form 
despite therapy. Measuring the size of proximal spinal nerve roots can serve as an 
approximation for tumor volume [5]. The volume of proximal peripheral nerves was 
determined in mice treated with early imatinib 0, 10, 25, 50, or 100 mg/kg/day (starting at 1 
month of life) for 12 weeks followed by euthanasia at 4 months of life. A second 
contemporaneous cohort of mice was treated with imatinib 0, 50, or 100 mg/kg/day for 12 
weeks followed by a 20-week observation period before euthanasia at approximately 9 
months of life, as described above. In the mice euthanized at 4 months, there was no 
significant reduction in the volume of proximal nerve roots compared to mice treated with 
vehicle control (Fig 3A). For the older cohort of mice treated with either 50 or 100 
mg/kg/day of imatinib for 12 weeks and euthanized at roughly 9 months of life, proximal 
nerve root volume was significantly reduced compared to vehicle treated mice (Fig 3B).
The mean proximal nerve size of the control mice in the younger cohort was 0.659 mm3 
compared to 1.205 mm3 in the older cohort, representing an 83% increase in mean tumor 
size over the 20-week observation period in untreated mice. In contrast, the mice treated 
with 50 mg/kg/day of imatinib showed a slower growth rate over this observation period 
with a 46% increase in mean tumor size between the younger and older cohorts (0.526 mm3 
at 4 months of age immediately after treatment discontinuation; 0.766 mm3 at 9 months of 
age after 12 weeks of treatment and 20 weeks of observation). Additionally, the mice treated 
with 100 mg/kg/day of imatinib demonstrated only a 57% increase in mean tumor size 
(0.490 mm3 at 4 months of age immediately after treatment discontinuation; 0.771 mm3 at 9 
months of age after 12 weeks of treatment and 20 weeks of observation). Independent of the 
dose of imatinib, treated mice had lower mean tumor size immediately after treatment and 
after 20 weeks of observation post-treatment than control mice.
DISCUSSION
Plexiform neurofibromas are complex tumors arising within the nerve plexus that are often 
apparent in infants and young children with NF1 and afflict up to 50% of people with NF1. 
The growth of pNF, driven by somatic inactivation of NF1 [26], can lead to significant 
neurologic impairment, pain, disfigurement, and even mortality [27–29]. While growth rates 
can be unpredictable, progression is often most pronounced during childhood and complete 
surgical resection, the only established therapy, is rarely curative [30, 31]. Recent advances 
in the development of GEMMs that accurately recapitulate the growth kinetics and hallmark 
histopathological features of human pNF have led to insights regarding the cells of origin 
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and critical role for the tumor microenvironment in the genesis and progression of these 
tumors [4, 32]. Moreover, GEMMs have enabled testing of experimental therapeutics [5, 33–
35], several of which have delivered promising results in subsequent clinical trials [15, 19].
Previous genetic and bone marrow transplant experiments in GEMMs have established that 
tumorigenic Schwann cells secrete excessive quantities of kit-ligand (SCF) [36] and that kit/
kit-ligand is required for tumor initiation [5]. We previously demonstrated in 
Nf1flox/-;Krox20-Cre(+) mice that treatment with imatinib, a potent inhibitor of c-kit, in 
mice with established pNF leads to reduction in tumor number and size [5], which translated 
into a phase 2 clinical trial demonstrating the first successful treatment for reducing pNF 
volume [15]. A recent study by Liao et al. showed that while tumorous Schwann cells are 
the primary source of SCF that mediates mast cell chemotaxis in pNF, a marked reduction in 
mast cells only slightly influences tumor progression [22]. Thus, it is possible imatinib’s 
efficacy may be due to additional mechanisms beyond inhibition of c-kit. Alternatively, there 
are subtle differences between the Plp-Cre model used by Liao and colleagues that disrupts 
the c-kit ligand versus earlier adoptive transfer experiments that disrupt the c-kit receptor in 
all hematopoietic lineages [5] and may impact both mast cells and other c-kit positive cells 
as well.
While other effective targeted therapies, including selumetinib [19] have emerged, pNF 
regrowth following discontinuation of therapy and during drug holidays remains a challenge 
and complete responses to therapy are not observed. Furthermore, in preclinical models, 
preventative use of MEK inhibition has not altered the initial development of pNF [23]. The 
preclinical studies outlined here evaluated the pharmacologic potential of imatinib to 
fundamentally block tumor initiation and progression early in life.
By administering imatinib to Nf1flox/flox;PostnCre(+) mice starting at 1 month of age, prior 
to known pNF development, we were able to determine that 12 weeks of treatment 
significantly reduced tumor initiation, even at 10% of the MTD of imatinib at 10 mg/kg/day. 
The impact of imatinib on tumor growth following therapy, however, is unclear and patient 
responses have been variable (personal communication, Dr. Kent Robertson). In the present 
GEMM study, we found that early imatinib therapy largely prevented pNF initiation and 
significantly impaired development of these tumors at later timepoints even after prolonged 
discontinuation of drug. It is thus possible that imatinib leads to ablation of the initiating 
Schwann cell progenitors or induces a durable state of senescence. Additionally, the growth 
rate and volume of tumors that do form, as determined by proximal nerve size, was 
significantly reduced in mice treated with early imatinib and then observed for a prolonged 
period of 20 weeks before euthanasia. These findings indicate a sustained effect of imatinib 
on tumor growth velocity even after cessation of treatment.
The observation that early imatinib administration can blunt the tumorigenic capcity of Nf1-
deficient Schwann cell progenitors even after prolonged cessation of therapy is crucial in 
considering clinical treatment approaches. Specifically, these data support clinical evaluation 
of imatinib in infants and young children with NF1 associated pNF for prevention of tumor 
progression. This is an important consideration clinically since maximal pNF growth rates 
are seen in childhood and imatinib has been formulated for pediatric dosing down to 6 
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months of age. As growth of pNF during adulthood often plateaus, successfully preventing 
volume increases in childhood could have sustained effects. The kinetics of rebound tumor 
growth after cessation of imatinib also warrants further exploration and it is critically 
important to collect and compare these clinical data amongst paitents undergoing treatment 
with other targeted therapies such as MEK inhibitors.
Imatinib is best recognized for its use in the treatment of chronic myelogenous leukemia 
[37] for which it received FDA approval in 2003. Its primary long-term side effects are 
growth retardation and impaired bone health [38, 39]. These potential adverse effects are a 
concern in the setting of germline NF1, but could be mediated via intermittent dosing 
strategies until there is evidence of growth stabilization of pNF. Such an approach could 
reduce drug toxicities while potentially eliminating the physical impairment, pain, and 
disfigurement so often associated with these tumors.
Furthermore, clonal adaptation driven by genetic heterogeneity and kinome reprogramming 
[40, 41] is a scenario that commonly occurs in response to targeted chemotherapies. A 
distinct advantage of imatinib is that it targets a pathway extrinsic to tumorigenic Schwann 
cell progenitors. By disrupting a critical step in tumor initiation, the kit/kit-ligand dependent 
recruitment of tumor inciting mast cells to the microenvironment, this approach may avoid 
classical selective pressures for clonal evolution and ultimately tumor resistance generated 
by inhibiting intrinsic tumor cell kinases. In the present study, tumors that did emerge in the 
genetically engineered mice treated preventatively with imatinib retained hallmark pNF-
associated histopathological features and we did not observe evidence of MPNST 
transformation in the imatinib-treated or vehicle groups.
Overall, we found administration of low-dose imatinib to young Nf1flox/flox;PostnCre(+) 
mice was sufficient to inhibit pNF genesis with durable response post-treatment, 
demonstrating promise for use of imatinib as a preventative agent for NF1 associated pNF. 
The next step is to identify the 25–50% of NF1 affected infants and young children who 
develop pNF [42, 43], where early pharmacologic interventions may have the largest benefit. 
Discovery of circulating biomarkers capable of detecting nascent, asymptomatic tumors 
during the earliest stages of initiation, otherwise unidentifiable by conventional imaging 
modalities, represents a potential step towards this goal. Further exploration of such 
approaches in the context of NF1 associated pNF is of critical importance to advancement of 
the field, thereby enabling future clinical trials aimed at early tumor prevention with 
imatinib or other targeted chemotherapies.
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Figure 1. Early imatinib mesylate prevents plexiform neurofibroma initiation in young 
Nf1flox/flox;PostnCre(+) mice.
(A) Schema depicting the experimental design. Cohorts of 1 month old 
Nf1flox/flox;PostnCre(+) mice were treated with 0–100 mg/kg/day imatinib beginning prior 
to tumor onset (vehicle control, n=4; 10 mg/kg/day, n=8; 25 mg/kg/day, n=8; 50 mg/kg/day, 
n=8; 100 mg/kg/day, n=5). Treatment was continued for 12 weeks, and mice were then 
euthanized to assess tumor burden. (B) Decrease in mean number of plexiform 
neurofibromas at all doses of imatinib used: 100 mg/kg/day and 10 mg/kg/day 
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(***p<0.001), 50 mg/kg/day and 25 mg/kg/day (****p<0.0001) as compared to vehicle 
treated controls. (C) Photomicrographs of hematoxylin and eosin stained sections 
demonstrating disrupted nerve architecture and increased cellularity in vehicle treated 
controls as compared to animals treated with imatinib 50–100 mg/kg/day (Panels 1–3). 
Masson’s trichrome stained sections show abundant fibroblast collagen deposition in vehicle 
treated nerve sections which is absent in mice undergoing preventative imatinib treatment 
(Panels 4–6). Infiltrating mast cells, marked with black arrows on representative toluidine 
blue stained sections, are nearly absent in mice treated preventatively with imatinib (Panels 
7–9).
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Figure 2. Sustained plexiform neurofibroma growth inhibition after early imatinib mesylate 
therapy followed by prolonged treatment cessation.
(A) Schema depicting the experimental design. Cohorts of 1 month old 
Nf1flox/flox;PostnCre(+) mice were treated preventatively with 50 mg/kg/day or 100 
mg/kg/day of imatinib for 12 weeks. Following discontinuation of therapy, mice were 
monitored for an additional 20 weeks prior to euthanasia to assess for tumor reemergence 
(vehicle control, n=10; 50 mg/kg/day, n=12; 100 mg/kg/day, n=12). (B) Significantly 
reduced mean plexiform neurofibroma number at 20 weeks after treatment discontinuation 
Armstrong et al. Page 13













at both 50 and 100 mg/kg/day dosing levels (****p<0.0001). (C) Photomicrographs of 
hematoxylin and eosin stained sections demonstrating disrupted nerve architecture and 
increased cellularity in vehicle treated controls as compared to animals treated with imatinib 
50–100 mg/kg/day and then observed for 20 weeks off treatment (Panels 1–3). Masson’s 
trichrome stained sections show abundant fibroblast collagen deposition in vehicle treated 
nerve sections which is absent in mice undergoing imatinib treatment followed by 
observation (Panels 4–6). Infiltrating mast cells, marked with black arrows on representative 
toluidine blue stained sections, are notably diminished in mice treated with imatinib and 
then observed (Panels 7–9).
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Figure 3. Early imatinib mesylate treatment reduces residual tumor volume in 
Nf1flox/flox;PostnCre(+) mice treated preventatively and then observed off treatment.
(A) There was no significant difference in proximal nerve size, an estimation for tumor 
volume, in 4 month old Nf1flox/flox;PostnCre(+) mice following 12 weeks of imatinib versus 
vehicle control (vehicle control, n=4; 10 mg/kg/day, n=8; 25 mg/kg/day, n=8; 50 mg/kg/day, 
n=8; 100 mg/kg/day, n=5). (B) In 9 month old Nf1flox/flox;PostnCre(+) mice initially treated 
with 50 or 100 mg/kg/day of imatinib for 12 weeks starting at 1 month of age, and then 
observed off treatment for 20 weeks, there was a significant reduction in proximal nerve size 
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in comparison to vehicle control (vehicle control, n=10; 50 mg/kg/day, n=12; 100 mg/kg/
day, n=12) (***p<0.001).
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